Compare ONFO & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONFO | SCNI |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2M | 1.2M |
| IPO Year | 2022 | 2014 |
| Metric | ONFO | SCNI |
|---|---|---|
| Price | $0.74 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 51.5K | ★ 92.9K |
| Earning Date | 11-17-2026 | 08-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,730,218.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 36.48 | N/A |
| 52 Week Low | $0.21 | $0.21 |
| 52 Week High | $27.00 | $3.58 |
| Indicator | ONFO | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 63.26 | 29.19 |
| Support Level | $0.46 | $0.42 |
| Resistance Level | $1.00 | $0.71 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 53.02 | 23.39 |
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Pace Generative.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.